Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The latest breakthroughs at Day One Biopharmaceuticals—from OJEMDA trial readouts to PTK7 ADC progress—are often hidden inside dense SEC prose. Those pages hold the cash-runway figures and regulatory milestones that can shift DAWN’s valuation overnight. If you have ever searched for “Day One Biopharmaceuticals insider trading Form 4 transactions” or wondered how an FDA feedback letter surfaces in an 8-K, you know the challenge of decoding these documents.
Stock Titan’s AI turns that challenge into clarity. Our platform delivers each Day One Biopharmaceuticals annual report 10-K simplified, pulls the numbers you need from every Day One Biopharmaceuticals quarterly earnings report 10-Q filing, and streams Form 4 insider transactions real-time. Interactive summaries translate oncology jargon into plain English so you’re understanding Day One Biopharmaceuticals SEC documents with AI, not sifting through footnotes. Track pipeline spend, compare segments, and see 8-K material events explained the moment they hit EDGAR.
Because Day One’s future rides on pediatric low-grade glioma data and milestone payments, we link each disclosure to what matters: development timelines in MD&A, cash tables for burn-rate analysis, and the Day One Biopharmaceuticals proxy statement executive compensation that aligns leadership incentives. Need a Day One Biopharmaceuticals earnings report filing analysis before the next capital raise? Want alerts on Day One Biopharmaceuticals executive stock transactions Form 4? It’s all here, continuously updated. In short, Day One Biopharmaceuticals SEC filings explained simply—including every Day One Biopharmaceuticals 8-K material events explained and more—so you can act with confidence.
Day One Biopharmaceuticals reported insider trading activity for Michael Vasconcelles, Head of Research and Development, who received significant equity compensation on June 16, 2025:
- Stock Options: Granted 346,000 options to purchase common stock at $6.64 per share, vesting over 4 years (25% after first year, then monthly)
- Restricted Stock Units (RSUs): Awarded 226,000 RSUs with zero exercise price, vesting over approximately 4 years (25% in August 2026, remaining quarterly)
The equity grants suggest a long-term retention strategy for this key executive, with the options expiring June 15, 2035. The combined award of performance-based options and time-vested RSUs represents a significant compensation package aimed at aligning the executive's interests with shareholders while providing both upside potential and guaranteed value through RSUs.
Day One Biopharmaceuticals (DAWN) has filed a Form 3 (Initial Statement of Beneficial Ownership) for Michael Vasconcelles, who has joined the company as Head of Research and Development. The filing date is June 28, 2025, with the triggering event occurring on June 16, 2025.
Key details of the filing:
- The reporting person currently owns no securities (derivative or non-derivative) of the company
- The filing is made individually, not as part of a group
- The reporting person serves as an Officer (Head of Research and Development) but is not a Director or 10% Owner
- The form was signed by Charles N. York II as Attorney-in-Fact on June 18, 2025
This Form 3 filing is a standard regulatory requirement for new officers under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future transactions and holdings reporting.
FAQ
What is the current stock price of Day One Biopharmaceuticals (DAWN)?
What is the market cap of Day One Biopharmaceuticals (DAWN)?
What is the core focus of Day One Biopharmaceuticals?
Which patient populations does Day One primarily serve?
What are the key therapeutic areas the company addresses?
Can you describe the significance of OJEMDA?
What distinguishes Day One's scientific approach?
How does Day One enhance its development pipeline?
Is there a focus on rare diseases within the company’s strategy?
How is the company positioned within the competitive biopharmaceutical landscape?
What role do strategic partnerships play at Day One?
How does Day One ensure the quality and safety of its therapies?
